Ind-Swift Laboratories Ltd
NSE: INDSWFTLAB BSE: 532305
₹370.55
+26.80 (7.80%)
Fri, 06 Nov 2026, 07:49 pm
Market Cap (in Cr)2980.61
PE Ratio38.39
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KInd-Swift Laboratories Ltd Company History
2000
- The Company developed a new drug ASTROVASTATIN.
- The Company allotted 7,43,300 non-cumulative, redeemable preference shares to promoters and associates.
- The Unit Trust of India picked up 5,00,000 equity shares of the company.
- The Company entered into exclusive marketing agreements with major international pharma companies.
- Ind-Swift Laboratories agreed to source requirements for Clarithromycin, Fexofenadine, Roxithromycin, and Candesartan from international pharmaceutical companies.
2002
- The Board forfeited 1,75,900 equity shares on which allotment money was due since 19th July, 1997.
2003
- The board approved the issue of 2322750 equity shares upon conversion of preference shares into equity shares.
- Ind-Swift Ltd., the promoter company, disinvested 386930 equity shares of the company.
2004
- The Company set up a subsidiary in the US.
- Ind-Swift Laboratories shifted its corporate and head office to SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101.
- The Company received the achievement award for the Best Performing Company in Category E by the Express Pharma Pulse.
- Ind Swift Laboratories entered into long-term agreements for the supply of APIs.
- The Company won the Deloitte Fast 500 Award 2004 in Hong Kong.
2005
- Ind Swift Laboratories put three new units into operation.
- The Company recommended a dividend of 15%.
2006
- Ind Swift Laboratories inaugurated its state of art R&D centre.
- Ind-Swift Labs opened an R&D centre in Mohali.
- The Company recommended a dividend of 15% on the equity shares and Re 1/- per share on the preference shares.
- The Company received the Bhartiya Udyog Rattan Award for its contribution to society and national development.
2007
- The Company successfully completed USFDA inspection for Clarithromycin API manufacturing facility.
- The Company recommended a dividend of 10% on the Equity Shares of the Company.
2008
- The Board recommended a dividend of 10% on the Equity Shares of the Company.
- Sh. S.R. Mehta was nominated as the Chairman of the Company.
- Sh. N.R. Munjal was nominated as the Vice-Chairman of the Company.
- Sh. V.K. Mehta was nominated as the Managing Director of the Company.
- The Registered Office of the Company was shifted to SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101.
2009
- The Board recommended a dividend of 10% on the Equity Shares of the Company.
- The Company appointed Mr. H P S Chawla, Mr. N D Aggarwal, and Mrs. Nirmal Aggarwal as Independent Directors.
2010
- The Board recommended a dividend of Rs. 1/ per share of Rs. 10/- each.
- Dr. N. P. Singh was appointed as an Independent Director.
2011
- Ind-Swift Laboratories received TGA approval from Australia for its seven APIs.
- Ind-Swift Labs filed two more DMFS with USFDA.
- The Board recommended a dividend of Rs 1/- per share on Equity Shares of Rs.10/- each.
- Ind-Swift Laboratories received PMDA approval for Pioglitazone and Risedronate Sodium from the Government of Japan.
2012
- Ind-Swift Laboratories launched generic formulations of the drug Atorvastatin in the UK in collaboration with Wockhardt UK Ltd.
- Ind-Swift Labs received USFDA approval for 5 APIs for its Derabassi facility.
- Ind-Swift Labs got its first order for contract research.
- Ind-Swift Labs received PMDA approval for Pioglitazone and Risedronate Sodium from the Government of Japan.
2013
- R K Ummat was appointed as an Independent Director on the Board of the Company.
2014
- Dr. Vinay Kumar Arora was appointed as an Independent Director.
2018
- The company acquired KEC Bikaner Sikar Transmission Private Limited.
2020
- Ind-Swift Labs tied up with a reputed generic player in the USA to launch generic Fexofenadine.
2021
- Ind-Swift Laboratories Limited received the North India Best Employer Award.
